Moderna Inc is trading 4% down today at $45.81, sliding alongside a broader pullback in tech and growth stocks as investors react to higher-for-longer rate concerns and macro volatility.
- The move extends weakness from a sharp drop on June 5, despite recent positive sentiment surrounding the company's infectious disease and oncology pipeline.
- Recent clinical developments include UK clearance for a Lynch syndrome mRNA cancer vaccine trial and renewed attention on hantavirus vaccine candidates.